Xenothera
Nantes
About Xenothera
Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases. Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera. Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $31.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Jun 2021)
- Website: xenothera.com
- Phone: +33240412987
Industries & Categories
Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/xenothera-24461 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.